Sugi Predict

Sugi Predict / Compounds / SCHEMBL9509924

SCHEMBL9509924

SCHEMBL9509924

CC(C)CN1CCN(CC(C)C)C1=O

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 7/20 0.56
▸ HDAC1 Q13547 1/20 0.47
▸ POLB P06746 1/20 0.41
▸ CYP1A1 P04798 3/20 0.38
▸ P2RX7 Q99572 1/20 0.36
▸ PER2 O15055 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ TSHR P16473 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11929087 0.91 PIK3CD (0.48) PIK3CDHDAC1POLBCYP1A1P2RX7
SCHEMBL10585201 0.90 PIK3CD (0.63) PIK3CDHDAC1POLBCYP1A1PER2
SCHEMBL20363457 0.87 PIK3CD (0.46) PIK3CDHDAC1POLBCYP1A1NPC1
SCHEMBL20363466 0.87 PIK3CD (0.46) PIK3CDHDAC1POLBCYP1A1P2RX7
SCHEMBL10150919 0.86 PIK3CD (0.50) PIK3CDHDAC1POLBCYP1A1PER2
SCHEMBL13187969 0.84 PIK3CD (0.47) PIK3CDHDAC1POLBCYP1A1P2RX7
SCHEMBL10121114 0.84 PER2 (0.50) PIK3CDHDAC1POLBCYP1A1PER2
SCHEMBL8653168 0.78 HDAC1 (0.44) PIK3CDHDAC1POLBCYP1A1P2RX7
SCHEMBL8284333 0.78 PIK3CD (0.55) PIK3CDHDAC1POLBPER2ALDH1A1
SCHEMBL22700986 0.77 PIK3CD (0.35) PIK3CDHDAC1PER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-1034966-A — — None — — JP disclosed
US-11730726-B2 Dimeric immuno-modulatory compounds against cereblon-based mechanisms H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) 2023-08-22 — — US disclosed
US-20230146870-A1 METHOD TO QUANTIFY AFFINITY AND SELECTIVITY OF SMALL MOLECULES FOR PROTEINS IN LIVING CELLS OHIO STATE INNOVATION FOUNDATION 2023-05-11 — — US disclosed
US-10752611-B2 Benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2020-08-25 — — US disclosed
US-10017499-B2 Benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2018-07-10 — — US disclosed
US-10017499-B2 Benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2018-07-10 — — US disclosed
US-9765087-B2 Benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2017-09-19 — — US disclosed
US-9765087-B2 Benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2017-09-19 — — US disclosed
US-20170114046-A1 NOVEL BENZIMIDAZOLE DERIVATIVES ENANTA PHARM INC (US) 2017-04-27 — — US disclosed
US-20170114046-A1 NOVEL BENZIMIDAZOLE DERIVATIVES ENANTA PHARM INC (US) 2017-04-27 — — US disclosed
US-8242156-B2 Linked dibenzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2012-08-14 — — US disclosed
US-20120076756-A1 NOVEL BENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2012-03-29 — — US disclosed
US-8101643-B2 Benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2012-01-24 — — US disclosed
US-20100260715-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2010-10-14 — — US disclosed
US-20100233122-A1 NOVEL BENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2010-09-16 — — US disclosed
US-20100233122-A1 NOVEL BENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2010-09-16 — — US disclosed
US-20100221215-A1 LINKED DIBENZIMIDAZOLE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2010-09-02 — — US disclosed
EP-0345513-B1 POLYARYLENEETHERS HAVING BENZOXAZOLE GROUPS AND PROCESS FOR THEIR PREPARATION BAYER AG (DE) 1993-09-08 — — EP disclosed
US-4960855-A Polyarylene ether containing benzoxazole groups and a process for their preparation BAYER AKTIENGESELLSCHAFT (DE) 1990-10-02 — — US disclosed
EP-0301270-A2 Process for the preparation of tetra-substituted cyclic ureas and cyclic ureas BAYER AG (DE) 1989-02-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170114046-A1 NOVEL BENZIMIDAZOLE DERIVATIVES EIF2AK2, ZC3HAV1, HAVCR2 PIK3CD 601/4885HDAC1 30/4885POLB 381/4885
US-11730726-B2 Dimeric immuno-modulatory compounds against cereblon-based mechanisms CRBN, CD4, CD74 PIK3CD 1758/4885HDAC1 2597/4885POLB 4462/4885
US-20120076756-A1 NOVEL BENZIMIDAZOLE DERIVATIVES EIF2AK2, ZC3HAV1, HAVCR2 PIK3CD 601/4885HDAC1 30/4885POLB 381/4885
US-20100260715-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, SLC10A1, EIF2AK2 PIK3CD 739/4885HDAC1 441/4885POLB 682/4885
US-20100233122-A1 NOVEL BENZIMIDAZOLE DERIVATIVES EIF2AK2, ZC3HAV1, HAVCR2 PIK3CD 601/4885HDAC1 30/4885POLB 381/4885
US-20100221215-A1 LINKED DIBENZIMIDAZOLE DERIVATIVES EIF2AK2, NSUN2, ZC3HAV1 PIK3CD 736/4885HDAC1 140/4885POLB 397/4885
US-10017499-B2 Benzimidazole derivatives EIF2AK2, ZC3HAV1, ZC3HAV1L PIK3CD 828/4885HDAC1 37/4885POLB 460/4885
US-10752611-B2 Benzimidazole derivatives EIF2AK2, ZC3HAV1, ZC3HAV1L PIK3CD 828/4885HDAC1 37/4885POLB 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.